1Garicia-Tsao G.Current managment of the complications of cirrhosis and portal hypertension: variceal hemorrhage,ascites,and spontaneous bacterial peritonitis[J].Gastroemterology,2001,120(3 ):726-748.
2Fernandez J,Navasa M,Gomez J,et al. Bacterial infections in cirrhosis:epidemiological changes with invasive procedures and norfioxacin prophylaxis[J].Hepatology,2002,35(1):140-148.
3Rimola A,Garca-Tsao G,Navasa M,et al.Diagnosis treatment and prophylaxis of spontaneous bacterial peritonitis:a consensus document[J].J Hepatol,2000,32( 1 ): 142.
4Moors KP, Wong F, Gines P, et al.The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club[J].Hepatology,2003,38(1):258.
5Sandhu BS,Gupta R,Sharma J,et al. Norfloxacin and cisapride compination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites[J]. J Gastroenterol Hepatol,2005, 20(4):599-605.
5Navasa M，Follo A，Llovet JM，et a1．Randomized,comparative study of oral oflaxacin versus intravenous cefstaxime in spontaneous bacterial peritonitis[J]．Gastroenterology,1996．111：1011.
3Malinchoc M,Kamath PS,Gordon FD,et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts [J]. Hepatology, 2000,31 (4) : 864-871.
4Stewart CA, Mayo ClinMiles, Malinchoc M,et al. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease [J]. Liver Transplantation, 2007,13 (10) : 486-488.
5Kamath PS,Kim WR. The model for end-stage liver disease (MELD) [J]. Hepatology, 2007,45 (3) :264-270.
